Edition:
United Kingdom

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

2.37USD
23 Feb 2018
Change (% chg)

$0.01 (+0.42%)
Prev Close
$2.36
Open
$2.36
Day's High
$2.38
Day's Low
$2.34
Volume
129,068
Avg. Vol
235,164
52-wk High
$3.93
52-wk Low
$2.20

Chart for

About

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the... (more)

Overall

Beta: 2.67
Market Cap(Mil.): $405.56
Shares Outstanding(Mil.): 128.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Celldex Therapeutics initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma

* Celldex Therapeutics Inc initiates phase 2 combination study of CDX-3379 and Cetuximab in head and neck squamous cell Carcinoma Source text for Eikon: Further company coverage:

17 Nov 2017

BRIEF-Celldex Therapeutics Q3 loss per share $0.20

* Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

07 Nov 2017

Earnings vs. Estimates